Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RHOA | P61586 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30080693 | 0.86 | L3MBTL1 (0.75) | L3MBTL1ALDH1A1HPGDTSHRHIF1A | |
| SCHEMBL4935101 | 0.86 | L3MBTL1 (0.75) | L3MBTL1ALDH1A1HPGDTSHRHIF1A | |
| SCHEMBL29084588 | 0.85 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1KMT2AHPGDCYP2C9 | |
| SCHEMBL30584232 | 0.85 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1KMT2AHPGDCYP2C9 | |
| SCHEMBL4936433 | 0.85 | RXFP1 (0.57) | L3MBTL1ALDH1A1KMT2AHPGDCYP2C9 | |
| SCHEMBL3167279 | 0.84 | HPGD (0.57) | L3MBTL1ALDH1A1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL4936465 | 0.83 | L3MBTL1 (0.55) | L3MBTL1ALDH1A1KMT2ACYP2C9TSHR | |
| SCHEMBL1264254 | 0.81 | L3MBTL1 (0.52) | L3MBTL1ALDH1A1HPGDCYP2C9TSHR | |
| SCHEMBL922842 | 0.81 | KDM4E (0.61) | L3MBTL1ALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL30584235 | 0.81 | KDM4E (0.61) | L3MBTL1ALDH1A1HPGDSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1656073-B | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | NOVARTIS AG | 2010-05-26 | — | — | CN | disclosed |
| US-7652022-B2 | N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; | NOVARTIS AG (CH) | 2010-01-26 | — | — | US | disclosed |
| EP-1511730-B8 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| CN-100427483-C | Anthranilic acid amide derivatives and their pharmaceutical use | NOVARTIS AG (CH) | 2008-10-22 | — | — | CN | disclosed |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | FLOERSHEIMER ANDREAS | 2006-06-15 | — | — | US | disclosed |
| US-20060128684-A1 | Anthranilic acid amide derivatives and their pharmaceutical use | BOLD GUIDO | 2006-06-15 | — | — | US | disclosed |
| CN-1720244-A | Anthranilic acid amide derivatives and their pharmaceutical use | NOVARTIS AG (CH) | 2006-01-11 | — | — | CN | disclosed |
| EP-1572686-A1 | ANTHRANILIC ACID AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE | Novartis AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| CN-1656073-A | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2005-08-17 | — | — | CN | disclosed |
| EP-1511730-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2005-03-09 | — | — | EP | disclosed |
| WO-2004052884-A1 | ANTHRANILIC ACID AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVARTIS AG (CH) | 2004-06-24 | — | — | WO | disclosed |
| WO-2003099771-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | UCK2, PRKDC, PRKACA | L3MBTL1 2936/4885ALDH1A1 3040/4885KMT2A 1452/4885 |
| US-20060128684-A1 | Anthranilic acid amide derivatives and their pharmaceutical use | AADAC, AADAT, NAAA | L3MBTL1 4724/4885ALDH1A1 801/4885KMT2A 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.